TAO WU to Antibodies, Monoclonal, Humanized
This is a "connection" page, showing publications TAO WU has written about Antibodies, Monoclonal, Humanized.
Connection Strength
0.485
-
HLX07 alone or combined with serplulimab, cisplatin and 5-fluorouracil for advanced esophageal squamous cell carcinoma: A phase 2 study. Cancer Commun (Lond). 2024 Dec; 44(12):1431-1443.
Score: 0.165
-
Efficacy and safety of camrelizumab plus apatinib in patients with advanced esophageal squamous cell carcinoma previously treated with immune checkpoint inhibitors (CAP 02 Re-challenge): A single-arm, phase II study. Eur J Cancer. 2024 Nov; 212:114328.
Score: 0.164
-
Tislelizumab and radiation therapy in low-risk early-stage extranodal natural killer/T-cell lymphoma, nasal type: a phase II study protocol. Future Oncol. 2024 Feb; 20(5):245-256.
Score: 0.155